

PTO/PC¹ Rec'd 06 FEB 2002

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/22060

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01K 67/00, 67/033; A61K 38/43; C07K 1/00; C12N 9/00

US CL : 424/94.1; 435/183; 514/2; 530/348.25; 800/8, 9, 13, 18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/94.1; 435/183; 514/2; 530/348.25; 800/8, 9, 13, 18

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, CAPLUS, WEST2.0, GENCORE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenCore Accession No. WO4334, 29 December 1996, BEAUDOIN et al., WO 96/32471 A2 (UNIV. SHERBROOKE) 17 October 1996, see abstract.	1-3, 6-14
X	MARCUS et al. The Endothelial Cell Ecto-ADPase Responsible for Inhibition of Platelet Function is CD39. J. Clinical Investigation. March 1997, Vol. 99, No. 6, pages 1351-1360, see entire article.	1-3, 6-14
X	KACZMAREK et al. Identification and Characterization of CD39/Vascular ATP Diphosphohydrolase. J. of Biological Chemistry. 20 December 1996, Vol. 271, No. 51, pages 33116-33122, see entire article.	1-3, 6-14

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 OCTOBER 2000

Date of mailing of the international search report

14 NOV 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CARRIE MARLENE STROUP

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US00/22060**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GAYLE et al. Inhibition of Platelet Function by Recombinant Soluble Ecto-ADPase/CD39. J. of Clinical Investigation. May 1998, Vol. 101, No. 9, pages 1851-1859, see entire article.	1-3, 6-14
Y	GUTH et al. Antagonism of the GPIIb/IIIa Receptor with the Nonpeptidic Molecule BIBU52: Inhibition of Platelet Aggregation In Vitro and Antithrombotic Efficacy In Vivo. J. of Cardiovascular Pharmacology. August 1997, Vol. 30, No. 2, pages 261-272, see entire article.	17, 19-24